TIVERTON, ON – September 4, 2019 – Bruce Power, Nordion, and Xcision have entered into a collaborative framework agreement to support the use of Cobalt-60 and the GammaPod™ for life-saving cancer treatments. “The GammaPod is an amazing technology that could shorten the course of treatment,…
OTTAWA, April 1, 2019 /CNW/ – Nordion (Canada) Inc. a Sotera Health Company, announces the purchase of Cobalt-60 from the Board of Radiation and Isotope Technology (BRIT), a unit of the Government of India Department of Atomic Energy, for distribution to Europe. The collaboration combines Indian-developed technology to…
OTTAWA, CANADA – March 26, 2019 – Nordion (Canada) Inc., a Sotera Health Company, has signed an amendment to an existing agreement with Tong Xing (Beijing) Nuclear Technology Co. Ltd. (TXNTC), a subsidiary of China Isotope & Radiation Corporation (HK. 01763) to supply Nordion with…
OTTAWA, Feb. 28, 2019 – Nordion (Canada) Inc., a Sotera Health Company, announces the acquisition of technology patents related to the production of Cobalt-60 in Light Water Reactors (LWRs) from GE-Hitachi Nuclear Energy Americas LLC (GEH). Nordion plays a significant role in safeguarding global health…
Nordion’s increased focus on gamma technologies supports Sotera Health’s company-wide commitment to Safeguarding Global Health™
BROADVIEW HEIGHTS, OH – August 6, 2018 – Sotera Health LLC, the world’s leading, fully integrated protector of global health, today announced the closing of the sale of the Medical Isotopes segment within its Nordion business to BWX Technologies…
Sotera Health committed to Safeguarding Global HealthTM with Nordion’s increased focus on global gamma technologies business
BROADVIEW HEIGHTS, OH – April 17, 2018 – Sotera Health LLC, the world’s leading, fully integrated protector of global health, today announced that it has entered into a definitive asset purchase agreement to sell the Medical Isotopes segment of its…
Nov 23, 2017- Successful collaboration between leading players in Canada’s nuclear industry assures a stable and reliable supply of Cobalt-60 for use in healthcare and other applications that benefit millions of people around the world.
For the past six decades, High Specific Activity (HSA) Cobalt-60, used in the treatment of cancer, has been produced in Canada…
CLEVELAND, OH. – Oct. 31, 2017—Sterigenics International LLC announced today that it has acquired Toxikon Europe N.V., the European division of Toxikon Corporation, a Bedford, Mass.-based preclinical contract research organization. Terms of the deal were not disclosed.
BALTIMORE, MD and BROADVIEW HEIGHTS, OH – October 3, 2017—Noxilizer, Inc. and Sterigenics International LLC announce the signing of a global agreement that will make Sterigenics the exclusive worldwide provider of nitrogen dioxide (NO2) contract sterilization services, as well as feasibility and research studies, to the pharmaceutical, biotech and medical device manufacturing industries.
COLUMBIA, MO, March 29, 2017—The University of Missouri Research Reactor (MURR®) and its partners Nordion, a business of Sterigenics International, and General Atomics (GA), announce that MURR’s License Amendment Request (LAR) has been submitted to the U.S. Nuclear Regulatory Commission (NRC). This marks a critical step towards implementing domestic U.S. production of molybdenum-99 (Mo-99). Once operational, production from this facility will be capable of supporting nearly half of U.S. demand for Mo-99, which currently must be imported from outside North America.